Bioxytran's Groundbreaking Stroke & Alzheimer's Tech Gains Validation That Measures Oxygenation Uptake During Strokes
Mongolian Gerbil Research Unlocks Critical Insights for Ischemic Stroke and Neurodegenerative Disease Treatments
BOSTON, MASSACHUSETTS, June 03, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the 'Company'), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer's disease, announced that Bioxtran's Science Advisor Prof. Avraham Mayevsky's book titled The Mongolian Gerbil Brain: Mitochondrial Function, Vasculature, and Pathophysiological States was published by a publishing house, Springer. It is available by eBook or Hardcover. The publication serves as a scientific cornerstone for Bioxytran's clinical development program of the universal oxygen carrier (UOC) in ischemic stroke and Alzheimer's disease, and is directly tied to the use of the MDX Viewer as an analytical method to detect a brain regions response to the addition of a UOC. The device has FDA approval to measure tissue oxygenation.
https://link.springer.com/book/10.1007/978-3-031-69549-0
Bioxytran is pioneering a transformative approach to treating ischemic stroke and neurodegenerative disease. The UOC is capable of replacing hyperbaric oxygen treatment (HBOT) by efficiently delivering therapeutic type of oxygen at the cellular level versus a charged version of oxygen prevalent in HBOT treatment called reactive oxygen species (ROS). This breakthrough is powered by the MDX viewer that provides real-time metabolic insights – a crucial element of Bioxytran's regulatory approach.
The Mongolian gerbil brain is special in that it lacks the vasculature compensatory mechanisms that can deal with decreased blood flow in the event of a stroke. Since the blood vessels in the Mongolian gerbil brain have no coping mechanism it makes them ideal in studying stroke pathophysiology. The research compiled in this publication further validates Bioxytran's scientific and clinical approach, positioning the company on the cutting edge of advancements in brain health and neuroprotective treatments.
'This research is paving the way for substantial advances in the understanding of the pathology of stroke and other neurodegenerative diseases, said Avraham Mayevsky, Member of Bioxytran's Medical Advisory Board. 'One of the biggest challenges in in clinical trials is determining the efficacy of a drug. This gerbil brain model has great predictive value in ischemic stroke and Alzheimer's disease. The gerbil model coupled with the MDX Viewer will provide us amazing insight in the pathogenesis of stroke and neurodegenerative diseases. Over 60 years went toward the development of the book which highlights a model of how brain anomalies are detected using this device.'
About Bioxytran, Inc.
Bioxytran, Inc. is at the forefront of developing complex carbohydrate-based therapeutics to address critical unmet medical needs in its three core platform technologies. These include virology, cancer metastasis, and oxygen transport. In addition to ProLectin-M, Bioxytran is advancing programs for pulmonary fibrosis and stroke treatment. When utilized by paramedics at the time of diagnosis BXT-25 has the possibility of reducing what is known as the time until needle by over 90%. For more information, visit www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
[email protected]
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words 'believe,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'plan,' and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
HVDC (High Voltage Direct Current) Transmission Industry Report 2025 - Global $19 Bn Market Trends, Opportunities, and Forecasts, 2020-2030: Demand for Long-Distance and Efficient Power Transmission
The HVDC Transmission Market presents opportunities in enhancing long-distance power delivery with minimal losses, especially for integrating renewables from remote locations to urban centers. Growth is driven by the need for efficient power infrastructure and cross-border projects, despite high capital costs. HVDC Transmission Market Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "HVDC Transmission Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to HVDC Transmission Market was valued at USD 12.98 Billion in 2024, and is expected to reach USD 19.05 Billion by 2030, rising at a CAGR of 6.44% HVDC (High Voltage Direct Current) transmission systems are increasingly adopted for long-distance power transmission due to their ability to minimize energy loss, enhance grid stability, and efficiently integrate renewable energy sources. These systems operate on direct current rather than alternating current, offering superior performance for transporting electricity over vast distances. Their strategic use in connecting remote renewable energy installations to urban centers, combined with growing investment in modernizing energy infrastructure, is accelerating market growth globally. Key Market Drivers Rising Demand for Long-Distance and Efficient Power TransmissionThe increasing requirement for reliable long-distance power delivery is significantly propelling the HVDC transmission market. As renewable energy projects - such as offshore wind farms and desert-based solar plants - are often situated far from major consumption zones, HVDC systems offer critical advantages including lower transmission losses and enhanced grid with vast and diverse geographies, such as China, India, and the U.S., particularly benefit from HVDC's capability to bridge large distances. The technology is also preferred in space-constrained areas and for undersea applications. Key projects like NordLink and the North Sea Wind Power Hub in Europe highlight HVDC's role in cross-border energy sharing. The expansion of ultra-high-voltage lines and ongoing deployment of over 300 projects worldwide further underscore the growing reliance on HVDC to support rising electricity demands and renewable energy Market Challenges High Initial Capital Investment and Long Payback PeriodThe HVDC transmission market faces a major hurdle in the form of substantial upfront capital expenditure. Establishing HVDC infrastructure requires costly equipment like converter stations, specialized cables, and advanced control technologies. The total expense often reaches billions of dollars, which limits accessibility for financially constrained entities and restricts adoption to well-funded or state-backed initiatives. Additionally, extended project timelines and long-term return on investment deter short-term-focused investors. Further complications arise from the complexity of permitting, regulatory approvals, and environmental assessments, which often cause cost overruns and delays. The limited pool of qualified manufacturers, including a few dominant players such as Hitachi Energy, Siemens Energy, and GE Vernova, adds to the challenge by constraining competition and increasing dependency on select Market Trends Expansion of Cross-Border HVDC Projects to Strengthen Regional Power GridsAn emerging trend in the HVDC transmission market is the growing number of cross-border projects aimed at reinforcing regional power networks and enabling efficient electricity trade. HVDC technology is increasingly recognized for its ability to transmit electricity over long distances with minimal losses, making it ideal for linking national grids. Europe is at the forefront with projects like Viking Link and NordLink, facilitating energy exchange and balancing renewable energy generation. Similar efforts in Asia and MENA regions focus on cross-border hydropower and solar integration. These projects not only bolster grid reliability and sustainability but also promote geopolitical collaboration and energy market efficiency. Advances in technologies like Voltage Source Converters and modular multilevel systems are further enhancing HVDC project feasibility, setting the stage for accelerated global deployment. Key Attributes: Report Attribute Details No. of Pages 180 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $12.98 Billion Forecasted Market Value (USD) by 2030 $19.05 Billion Compound Annual Growth Rate 6.4% Regions Covered Global Report Scope: Competitive LandscapeCompany Profiles: Detailed analysis of the major companies present in the Global HVDC Transmission Market. Hitachi Energy Ltd. Siemens Energy AG General Electric Company ABB Ltd. NR Electric Co., Ltd. Prysmian S.p.A. Nexans S.A. NKT A/S Toshiba Energy Systems & Solutions Corporation Mitsubishi Electric Corporation HVDC Transmission Market, By Type: High-power Rating Projects Low-power Rating Projects HVDC Transmission Market, By Technology: Line Commutated Converter (LCC) Voltage Source Converters (VSC) HVDC Transmission Market, By Application: Subsea Underground Overhead Mixed HVDC Transmission Market, By Region: North America United States Canada Mexico Europe France United Kingdom Italy Germany Spain Asia-Pacific China India Japan Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE Kuwait Turkey For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment HVDC Transmission Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
34 minutes ago
- Yahoo
Star Mountain Announces Exit of Channel Factory Investment
NEW YORK, June 05, 2025--(BUSINESS WIRE)--Star Mountain Fund Management, LLC ("Star Mountain") is pleased to announce its exit through the Truelink Investment in Channel Factory ("Company"). Truelink Capital is a Los Angeles–based private equity firm focused on Tech-Enabled Services and Industrials sectors. The transaction marks a successful exit for Star Mountain and other shareholders. Founded in 2014 by Tony Chen, Channel Factory is a trusted partner to the world's leading brands, agencies, and media buyers, delivering contextually targeted advertising solutions. Leveraging proprietary AI technology, Channel Factory helps advertisers maximize the efficiency of their digital media campaigns across YouTube, Meta, other walled gardens, and CTV. It ensures ads appear in brand-suitable, high-performing, and contextually relevant content. Since Star Mountain's investment, Channel Factory has successfully executed a number of valuable growth initiatives, including the expansion of its value proposition through strategic partnerships with Google and other social platforms, geographic expansion in Europe and Asia, and the professionalization of the management team, including the addition of experienced board members. "We thank the team at Star Mountain Capital for their support and guidance. As our first institutional capital partner, they helped our business grow and expand globally as we leveraged their significant expertise in the Advertising and Marketing industry. We are excited they will continue to be a minority owner in Channel Factory's next chapter of expansion," said Channel Factory Founder and CEO Tony Chen. "Since Star Mountain invested in Channel Factory, the company has been able to deliver outstanding growth and profitability. We're proud to remain shareholders at Channel Factory in this new cycle and confident that they will achieve even more success," said Bruce Eatroff, Star Mountain Managing Director. About Star Mountain Capital With over $4 billion in AUM (committed capital including debt facilities as of 5/31/2025), Star Mountain specializes in providing scalable and data-driven investment solutions across two core strategies: Direct Investments: Providing debt and equity capital to established lower middle-market businesses. Secondary Investments: Acquiring LP interests, direct assets, and making primary LP commitments. Star Mountain's investors include public and private pensions, insurance companies, commercial banks, endowments, foundations, family offices, and high-net-worth individuals. Employee-owned and sharing profits with 100% of its U.S. full-time employees, the firm prioritizes alignment of interests to maximize value for stakeholders. Since 2010, Star Mountain has completed over 300 direct investments and 50 secondary/fund investments in the North American lower middle-market. The firm has been recognized as one of the Inc. 5000 fastest-growing private companies and a Best Place to Work by Crain's New York Business and Pensions & Investments. For more information, visit Legal Disclaimer: This press release does not constitute an offer to sell or a solicitation of an offer to purchase interests in any investment product. Awards and recognitions by third-party rating agencies, companies, or publications should not be interpreted as a guarantee of future results or performance. They should not be considered as an endorsement, recommendation, or referral of Star Mountain Capital or its representatives by any client or third party. Rankings published by media and industry organizations are based on information provided by the recognized advisor. Additionally, readers should understand that past performance is not indicative of future results. Award descriptions and selection methodologies may vary. Awards and Recognition Disclosure: Star Mountain Capital's awards and recognitions are based on third-party evaluations and criteria, which may be subjective. These honors do not imply a guarantee of future performance or an endorsement by current or past clients. Ranking Methodologies: Crain's Best Places to Work: Evaluations were conducted through a two-part process, assessing workplace policies, practices, and employee satisfaction via surveys. Participation required a fee solely for survey processing purposes. More details are available at Crain's eligibility criteria. Pensions & Investments Best Places to Work: Companies were evaluated based on surveys measuring employee engagement (75%) and employer policies (25%). Participation required a minimum of 20 U.S. employees and $100 million in discretionary assets under management. Further details can be found at P&I eligibility criteria. Inc. 5000 Rankings: Companies were ranked based on revenue growth from 2019 to 2022. To qualify, firms had to be U.S.-based, privately held, and independent, with revenue thresholds of at least $100,000 in 2019 and $2 million in 2022. More details are available at Inc. 5000 criteria. View source version on Contacts Media Contact: John Polis – Media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
ASEAN Point of Care (POC) Diagnostics Market Report 2025-2030
Vietnam emerges as the fastest-growing market, bolstered by strong primary healthcare enhancements. The infectious disease testing segment is set to witness the highest growth, driven by advanced molecular and immunoassay technologies. ASEAN Point of Care Diagnostics Market Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "ASEAN Point of Care Diagnostics Market by Product (Infectious Disease (TB, Hepatitis, STDs, HAIs), Glucose, Cardiometabolic, Pregnancy, Coagulation), Technology (Lateral Flow Assays, Biochemistry, MDx), End User (Home Care, Hospitals) - Forecast to 2030" has been added to offering. The ASEAN point of care diagnostics market is projected to expand from USD 1.08 billion in 2025 to USD 1.36 billion by 2030, recording a CAGR of 4.7% over the forecast period. This growth is predominantly driven by favorable government policies and increased funding investments that bolster the demand for Point of Care (POC) testing across the ASEAN region. Governments in ASEAN countries are increasingly adopting POC technologies to enhance health access, reduce costs, and improve patient outcomes. Initiatives including strategic partnerships, research, and nationwide screening campaigns further promote POC usage, offering significant growth opportunities for diagnostic firms. In numerous developing regions where health infrastructure remains underdeveloped, POC devices facilitate the decentralization of diagnostics, thereby broadening access to essential testing. This report categorizes the market by product, technology, end user, and country. It comprehensively covers key growth drivers, restraints, opportunities, and challenges, providing insights into industry players, strategies, and recent developments. A competitive analysis of emerging ASEAN point-of-care diagnostics startups is also included. Key market players include Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Sysmex Corporation, and Danaher Corporation, among others. The report provides insights into the following points: Analysis of factors influencing market growth including the rise of infectious and chronic diseases, government initiatives, and public-private partnerships. Product Development/Innovation: Detailed insights into upcoming technologies and new product launches in the ASEAN market. Market Development: Comprehensive information on lucrative markets across ASEAN countries. Market Diversification: Insights into new products, untapped geographies, and investments. Competitive Assessment: In-depth analysis of leading players' market shares, strategies, and offerings. Infectious disease testing products anticipated to register the highest growth rate This market segment encompasses infectious disease testing products, glucose monitoring products, cardiometabolic testing products, among others. The infectious disease testing products segment's rapid growth is driven by ASEAN efforts to enhance disease surveillance. The frequency of infectious disease outbreaks and the need for rapid diagnosis, particularly in rural and urban healthcare settings, underpin this demand. Advances in molecular platforms and immunoassays further foster the sector's expansion. By technology, the Biochemistry segment accounted for the largest market share in 2024 The market is segmented into lateral flow assays, rapid tests, and biochemistry. Biochemistry held the largest share, attributed to its broad applicability in various essential tests such as glucose and electrolyte analysis. The high incidence of chronic diseases in ASEAN countries necessitates these diagnostics, with biochemistry testing's ease of use and cost-effectiveness making it ideal for decentralized healthcare environments. The demand for early disease detection further supports biochemistry's leading position in the market. Vietnam is the fastest-growing market for point of care diagnostics in the ASEAN region Within ASEAN, Vietnam is poised for the highest growth, largely due to its initiatives post-COVID-19 to strengthen primary healthcare and nationwide screening. Vietnam's commitment to enhancing healthcare infrastructure, particularly in infectious disease management, is evident in its robust surveillance systems. Their performance in global health security indicators emphasizes their capability to adopt POC diagnostics effectively. Key Attributes Report Attribute Details No. of Pages 334 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $1.08 Billion Forecasted Market Value (USD) by 2030 $1.36 Billion Compound Annual Growth Rate 4.7% Regions Covered Asia-Pacific Key Topics CoveredMarket Dynamics Drivers Rising Incidence of Infectious Diseases Increasing Prevalence of Chronic Diseases Favorable Government Initiatives for POC Testing Rising Number of Public-Private Partnerships (PPPs) Challenges Pricing Pressure on Manufacturers Stringent Regulatory Approval Process for Product Commercialization Opportunities Gradual Shift Toward Decentralized Healthcare Systems Availability of POC Tests with Multiplexing Capabilities Industry Trends Trends/Disruptions Impacting Customers' Businesses Companies Profiled in the ASEAN POC Market Abbott F. Hoffmann-La Roche Ltd. Siemens Healthineers AG Sysmex Corporation Danaher Corporation BD Quidelortho Corporation Cardinal Health bioMerieux EKF Diagnostics Holdings PLC Thermo Fisher Scientific Inc. Accubiotech, Co. Ltd. Biosynex SA SD Biosensor, Inc. Sekisui Diagnostics Werfen Trinity Biotech PTS Diagnostics Lifescan IP Holdings, LLC CTK Biotech, Inc. Wondfo Arkray, Inc. Xiamen Boson Biotech Co. Ltd. Credo Diagnostics Biomedical Pte. Ltd. Anbio Biotechnology Inc. SG Diagnostics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment ASEAN Point of Care Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
